Sinopep's Lianyungang facility has achieved another milestone in international regulatory compliance by securing the Certificate of Good Manufacturing Practices (CBPF-GMP) from ANVISA, the Brazilian Health Regulatory Agency and a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This accomplishment follows previous approvals from the U.S. FDA and South Korea's MFDS, underscoring Sinopep's commitment to global quality standards. The audit specifically covered the active pharmaceutical ingredients (APIs) Semaglutide and Liraglutide, and its success will significantly bolster the expansion of these products in international markets.

Guided by the company spirit of "Leading in time, advancing in technology" and the quality promise of "Quality First, Customer Foremost", Sinopep maintains rigorous quality standards at every stage of production. This dedication not only enhances global access to quality medicines but also reinforces the company's mission to safeguard human health worldwide.